Bioneer Corporation (064550) - Total Assets
Based on the latest financial reports, Bioneer Corporation (064550) holds total assets worth ₩376.52 Billion KRW (≈ $255.16 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Bioneer Corporation (064550) shareholders funds for net asset value and shareholders' equity analysis.
Bioneer Corporation - Total Assets Trend (2011–2024)
This chart illustrates how Bioneer Corporation's total assets have evolved over time, based on quarterly financial data.
Bioneer Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioneer Corporation's total assets of ₩376.52 Billion consist of 44.7% current assets and 55.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 12.1% |
| Accounts Receivable | ₩14.07 Billion | 4.2% |
| Inventory | ₩37.44 Billion | 11.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩4.53 Billion | 1.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Bioneer Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Bioneer Corporation market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioneer Corporation's current assets represent 44.7% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2024, up from 6.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 11.3% of total assets.
Bioneer Corporation Competitors by Total Assets
Key competitors of Bioneer Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
Bioneer Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.18 | 2.40 | 2.73 |
| Quick Ratio | 1.74 | 1.81 | 2.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩84.55 Billion | ₩98.10 Billion | ₩60.23 Billion |
Bioneer Corporation - Advanced Valuation Insights
This section examines the relationship between Bioneer Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.59 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.3% |
| Total Assets | ₩332.19 Billion |
| Market Capitalization | $157.84 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioneer Corporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bioneer Corporation's assets grew by 5.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bioneer Corporation (2011–2024)
The table below shows the annual total assets of Bioneer Corporation from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩332.19 Billion ≈ $225.12 Million |
+5.29% |
| 2023-12-31 | ₩315.49 Billion ≈ $213.80 Million |
+5.61% |
| 2022-12-31 | ₩298.74 Billion ≈ $202.45 Million |
+13.84% |
| 2021-12-31 | ₩262.42 Billion ≈ $177.84 Million |
+37.27% |
| 2020-12-31 | ₩191.17 Billion ≈ $129.55 Million |
+132.85% |
| 2019-12-31 | ₩82.10 Billion ≈ $55.64 Million |
+15.95% |
| 2018-12-31 | ₩70.81 Billion ≈ $47.98 Million |
+20.63% |
| 2017-12-31 | ₩58.70 Billion ≈ $39.78 Million |
-7.87% |
| 2016-12-31 | ₩63.71 Billion ≈ $43.18 Million |
-11.50% |
| 2015-12-31 | ₩71.99 Billion ≈ $48.78 Million |
+6.87% |
| 2014-12-31 | ₩67.36 Billion ≈ $45.65 Million |
-3.68% |
| 2013-12-31 | ₩69.93 Billion ≈ $47.39 Million |
+2.65% |
| 2012-12-31 | ₩68.13 Billion ≈ $46.17 Million |
-3.54% |
| 2011-12-31 | ₩70.63 Billion ≈ $47.87 Million |
-- |
About Bioneer Corporation
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analys… Read more